---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-23-000041"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:40:08.507067+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Phase 3 LUNAR trial meets primary endpoint: TTFields + SOC improves OS in NSCLC

## Summary
- Median OS 13.2 months for TTFields+SOC vs 9.9 months for SOC alone (HR 0.74, p=0.035).
- In ICI subgroup, median OS 18.5 vs 10.8 months (HR 0.63, p=0.03); in docetaxel 11.1 vs 8.7 months (HR 0.81, p=0.28).
- No added systemic toxicities; most common device effect was grade 1-2 dermatitis (43%).
- Company plans to submit for regulatory approval; first-line NSCLC studies underway.

## SEC filing metadata
- accession: 0001645113-23-000041
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000041/0001645113-23-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511323000041/nvcr-20230606.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-23-000041
- JSON: https://secwatch.observer/filing/0001645113-23-000041.json
- Plain text: https://secwatch.observer/filing/0001645113-23-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.